Yellow Fever Vaccine–Associated Viscerotropic Disease among Siblings, São Paulo State, Brazil
Eder Gatti Fernandes
, Victor Bertollo Gomes Porto, Patrícia Mouta Nunes de Oliveira, Amaro Nunes Duarte-Neto, Maria de Lourdes de Sousa Maia, Letícia Kegele Lignani, Juliana Silva Nogueira, Gabriellen Vitiello Teixeira, Silvia D’Andretta Iglezias, Roberta Morozetti Blanco, and Helena Keico Sato
Author affiliations: Instituto de Infectologia Emílio Ribas, São Paulo, Brazil (E.G. Fernandes); Centro de Vigilância Epidemiológica “Prof. Alexandre Vranjac,” São Paulo (E.G. Fernandes, H.K. Sato); Programa Nacional de Imunizações, Brasilia, Brazil (V.B.G. Porto); Bio-Manguinhos, Rio de Janeiro, Brazil (P.M.N. de Oliveira, M. de Lourdes de Sousa Maia, L.K. Lignani, G.V. Teixeira); Faculdade de Medicina da Universidade de São Paulo, São Paulo (A.N. Duarte-Neto); Instituto Adolfo Lutz, São Paulo (A.N. Duarte-Neto, J.S. Nogueira, S. D'Andretta Iglezias, R.M. Blanco)
Main Article
Figure 1
Figure 1. Timelines of reported cases of YFV–associated viscerotropic disease after 17DD vaccination during yellow fever epidemic, São Paulo state, Brazil, 2017–2018. Cases 1–2 were brothers and received standard doses. Cases 3–5 are siblings and received fractionated doses. ED, emergency department; ICU, intensive care unit; YFV, yellow fever vaccine.
Main Article
Page created: January 04, 2023
Page updated: February 19, 2023
Page reviewed: February 19, 2023
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.